We addressed the Advance Purchase Agreement (APA) and Purchase Agreement (PA) on our live-stream with Mario and Rita, and we are now presenting all of the material and links here.
With the agreement of BioNTech-Pfizer, the redacted Advance Purchase Agreement is available. The Purchase Agreement is also available
17th June 2020, European Commission presents a European strategy to accelerate the development, manufacturing, and deployment of vaccines against COVID-19. (English Version) (Maltese Version)
18th June 2020, Annex to the Decision of the European Commission on approving the agreement with Member States on procuring Covid-19 vaccines on behalf of the Member States and related procedures.
11th November 2020, European Commission approved a fourth contract with pharmaceutical companies BioNTech and Pfizer, which provides for the initial purchase of 200 million doses on behalf of all EU Member States, plus an option to request up to a further 100 million doses, to be supplied once a vaccine has proven to be safe and effective against COVID-19. Member States can decide to donate the vaccine to lower and middle-income countries or to re-direct it to other European countries.
21st December 2020, The European Commission has granted a conditional marketing authorisation (CMA) for the COVID‑19 vaccine developed by BioNTech and Pfizer, making it the first COVID-19 vaccine authorised in the EU.
8th January 2021, The European Commission today proposed to the EU Member States to purchase an additional 200 million doses of the COVID-19 vaccine produced by BioNTech and Pfizer, with the option to acquire another 100 million doses. This would enable the EU to purchase up to 600 million doses of this vaccine, which is already being used across the EU.
10th March 2021, European Commission has reached an agreement with BioNTech-Pfizer for the supply of four million more doses of COVID-19 vaccines for Member States in the next two weeks in order to tackle coronavirus hotspots and to facilitate free border movement.
20th May 2021, the European Commission signed a third contract with BioNTech-Pfizer. It reserves an additional 1.8 billion doses on behalf of all EU Member States, between the end of 2021 and 2023. It will allow for the purchase of 900 million doses of the current vaccine and of a vaccine adapted to variants (if necessary and if approved), with the option to purchase an additional 900 million doses.
19 December 2021, the Commission agreed with BioNTech-Pfizer to accelerate deliveries of 20 million vaccine doses in Member States during the first quarter of 2022 (5 million in January, 5 million in February, and 10 million in March), bringing the total number of deliveries for this period to 215 million.
13 May 2022, European Commission and BioNTech-Pfizer reached an agreement to better address Member States’ needs for COVID-19 vaccines. This agreement ensures that Member States have access to the vaccines when they need them – including future variant-adapted vaccines if authorised, so that they can quickly respond to any epidemiological developments and continue to support partner countries globally.
So, along with the future vaccines agreement will there be same terrible fate therefore: discrimination dictatorship and people manoeuvred into puppets. Is the farse ever going to stop!!
So, along with the future vaccines agreement will there be same terrible fate therefore: discrimination dictatorship and people manoeuvred into puppets. Is the farse ever going to stop!!